Hepatitis C market will reach US $15.5 billion in 2022 (Figure)
-
Last Update: 2013-09-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
In February this year, Geely announced the success of the fourth and final phase III research of sofosbuvir, and submitted the regulatory documents of sofosbuvir to FDA in April this year, making the company the first enterprise to apply to FDA for oral treatment of hepatitis C, while its competitors such as abbvie and Bristol Myers Squibb are still in the late stage of development in relevant fields If approved, sofosbuvir will become an important part of the first all oral combination therapy for hepatitis C and is expected to eliminate the need for traditional injectable drugs Fierce competition among several other pharmaceutical giants, including abbvie, JNJ and Bristol Myers Squibb, will also boost the growth of the hepatitis C market, as they compete to develop better interferon free therapies Sabada Dube, an epidemiologist at Datamonitor healthcare, said that despite current clinical breakthroughs, hepatitis C remains a huge public health problem around the world At present, there are about 7 million patients with hepatitis C in the United States, Japan and five major European markets (France, Germany, Italy, Spain and the United Kingdom) In addition to Japan, the number of patients in these markets is expected to increase Michael Haydock, an analyst at Datamonitor healthcare, said that traditional interferon therapy is poorly tolerated and lasts a long time, so the demand for new and improved interferon free therapies will only continue to grow.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
